Our analysis demonstrates that gBRCA testing for all patients with HER2-negative breast cancer, including TNBC and HR-positive HER2-negative breast cancer, is cost-effective and has a clinical benefit. This evidence concerns the gene ERBB2 and breast carcinoma.